Investors have filed a federal securities fraud class action against GeneDx Holdings Corp. (NASDAQ: WGS), alleging the genomic diagnostics company made materially false and misleading statements about the viability of its Fabric Genomics acquisition before disclosing a near-total write-down that erased roughly half the stock's value in a single trading session [1][2]. The suit, captioned Basma v. GeneDx Holdings Corp., No. 26-cv-00880, was filed in the U.S. District Court for the District of Connecticut [1].
The complaint covers investors who purchased WGS common stock between April 16, 2025 and May 4, 2026, a period during which defendants allegedly misrepresented the acquisition's business prospects and integration progress [1]. On May 4, 2026, GeneDx disclosed a $31.3 million goodwill impairment charge equal to approximately 94% of the total Fabric Genomics acquisition price [1][2]. The company simultaneously issued lower revenue guidance [1]. WGS shares fell approximately 49% on the day of that disclosure [2]. The impairment figure and the single-day price decline together frame the core injury alleged by the putative class.
The case proceeds under the Securities Exchange Act of 1934 and Rule 10b-5, the standard federal framework for investor fraud claims predicated on material misstatements or omissions [1]. Kessler Topaz Meltzer & Check LLP, a firm that regularly serves as lead counsel in securities class actions, is among the firms representing the proposed class [1]. Under the Private Securities Litigation Reform Act, investors have 60 days from the initial filing to move for appointment as lead plaintiff, a deadline that governs the near-term procedural calendar in this matter [1].
The lead-plaintiff motion period shapes what comes next. Institutional investors with the largest documented losses in WGS shares during the class period will have the strongest argument for appointment [1]. Once lead plaintiff and lead counsel are certified, defendants will have an opportunity to move to dismiss before any discovery proceeds, a hurdle that securities class actions must clear under the heightened pleading standards imposed by the PSLRA. The central factual question at that stage will be whether internal company records or public statements created a strong inference that defendants knew, or recklessly disregarded, that the Fabric Genomics integration was impaired well before the May 2026 disclosure.